S100B and hepatocellular carcinoma: The new S100 family members-based risk score model of HCC exhibited substantial heterogeneity in many aspects, including prognosis, genetic mutations, phenotypic traits (measured as scores in TCGA [22]), predictive therapeutic efficacy and the abundance of infiltrating immune cell.